nach oben

Breast Cancer

Erschienen in:

07.03.2018 | Original Article

The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines

Erschienen in: Breast Cancer | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The E3 ubiquitin ligase constitutive photomorphogenic 1 (COP1) mediates cell survival, growth, and development, and interacts with the tumor suppressor protein p53 to induce its ubiquitination and degradation. Recent studies reported that COP1 overexpression is associated with increased cell proliferation, transformation, and disease progression in a variety of cancer types. In this study, we investigated whether COP1 regulates p53-mediated cell cycle arrest and apoptosis in human breast cancer cell lines.

Methods

We downregulated COP1 expression using lentiviral particles expressing short hairpin RNA (shRNA) targeting COP1 and measured the effects of the knockdown in three different breast cancer cell lines.

Results

COP1 silencing resulted in p53 activation, which induced the expression of p21 and p53-upregulated modulator of apoptosis (PUMA) expression, and reduced the levels of cyclin-dependent kinase 2 (CDK2). Notably, knockdown of COP1 was associated with cell cycle arrest during the G₀/G₁ phase.

Conclusions

The COP1-mediated degradation of p53 regulates cancer cell growth and apoptosis. Our results indicate that COP1 regulates human breast cancer cell proliferation and apoptosis in a p53-dependent manner. These findings suggest that COP1 might be a promising potential target for breast cancer-related gene therapy.

Shah R, Rosso K, Nathanson SD. Pathogenesis, prevention, diagnosis and treatment of breast cancer. World J Clin Oncol. 2014;5(3):283–98. https://doi.org/10.5306/wjco.v5.i3.283.CrossRefPubMedPubMedCentral

Harbeck N, Gnant M. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2017;389(10074):1134–50. https://doi.org/10.1016/S0140-6736(16)31891-8.CrossRefPubMed

Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 2006;6:909–23. https://doi.org/10.1038/nrc2012.CrossRefPubMed

Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell. 2009;137:413–31. https://doi.org/10.1016/j.cell.2009.04.037.CrossRefPubMed

Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia. 2008;22:730–9. https://doi.org/10.1038/leu.2008.11.CrossRefPubMedPubMedCentral

Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002;14:86–91. https://doi.org/10.1097/00001622-200201000-00015.CrossRefPubMed

Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl). 2007;85:1175–86. https://doi.org/10.1007/s00109-007-0221-2.CrossRef

Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22:9030–40. https://doi.org/10.1038/sj.onc.1207116.CrossRefPubMed

Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408:307–10. https://doi.org/10.1038/35042675.CrossRefPubMed

10.

He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, et al. Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene. 2005;24:2929–43. https://doi.org/10.1038/sj.onc.1208474.CrossRefPubMed

11.

Nilausen K, Green H. Reversible arrest of growth in G1 of an established fibroblast line (3T3). Exp Cell Res. 1965;40:166–8. https://doi.org/10.1016/0014-4827(65)90306-X.CrossRefPubMed

12.

Bianchi E, Denti S, Catena R, Rossetti G, Polo S, Gasparian S, et al. Characterization of human constitutive photomorphogenesis protein 1, a RING finger ubiquitin ligase that interacts with Jun transcription factors and modulates their transcriptional activity. J Biol Chem. 2003;278:19682–90. https://doi.org/10.1074/jbc.M212681200.CrossRefPubMed

13.

Jain AK, Barton MC. Making sense of ubiquitin ligases that regulate p53. Cancer Biol Ther. 2010;10:665–72. https://doi.org/10.4161/cbt.10.7.13445.CrossRefPubMedPubMedCentral

14.

Deng XW, Caspar T, Quail PH. COP1: a regulatory locus involved in light-controlled development and gene expression in Arabidopsis. Genes Dev. 1991;5:1172–82. https://doi.org/10.1101/gad.5.7.1172.CrossRefPubMed

15.

Choi HH, Phan L, Chou PC, Su CH, Yeung SC, Chen JS, et al. COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth. Oncotarget. 2015;6:19721–34. https://doi.org/10.18632/oncotarget.3821.PubMedPubMedCentralCrossRef

16.

Vitari AC, Leong KG, Newton K, Yee C, O’Rourke K, Liu J, et al. COP1 is a tumor suppressor that causes degradation of ETS transcription factors. Nature. 2011;474:403–6. https://doi.org/10.1038/nature10005.CrossRefPubMed

17.

Li YF, Wang DD, Zhao BW, Wang W, Huang CY, Chen YM, et al. High level of COP1 expression is associated with poor prognosis in primary gastric cancer. Int J Biol Sci. 2012;8:1168–77. https://doi.org/10.7150/ijbs.4778.CrossRefPubMedPubMedCentral

18.

Marine JC. Spotlight on the role of COP1 in tumorigenesis. Nat Rev Cancer. 2012;12:455–64. https://doi.org/10.1038/nrc3271.CrossRefPubMed

19.

Dornan D, Bheddah S, Newton K, Ince W, Frantz GD, Dowd P, et al. COP1, the negative regulator of p53, is overexpressed in breast and ovarian adenocarcinomas. Cancer Res. 2004;64:7226–30. https://doi.org/10.1158/0008-5472.CAN-04-2601.CrossRefPubMed

20.

Ouyang M, Wang H, Ma J, Lu W, Li J, Yao C, et al. COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer. BMC Cancer. 2015;15:132. https://doi.org/10.1186/s12885-015-1151-y.CrossRefPubMedPubMedCentral

21.

Lu G, Zhang Q, Huang Y, Song J, Tomaino R, Ehrenberger T, et al. Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. Cancer Cell. 2014;26:222–34. https://doi.org/10.1016/j.ccr.2014.06.026.CrossRefPubMedPubMedCentral

22.

Kato S, Ding J, Pisck E, Jhala US, Du K. COP1 functions as a FoxO1 ubiquitin E3 ligase to regulate FoxO1-mediated gene expression. J Biol Chem. 2008;283:35464–73. https://doi.org/10.1074/jbc.M801011200.CrossRefPubMedPubMedCentral

23.

Wang L, He G, Zhang P, Wang X, Jiang M, Yu L. Interplay between MDM2, MDMX, PIRH2, and COP1: the negative regulators of p53. Mol Biol Rep. 2011;38:229–36. https://doi.org/10.1007/s11033-010-0099-x.CrossRefPubMed

24.

Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA. 2006;103:1888–93. https://doi.org/10.1073/pnas.0507493103.CrossRefPubMed

25.

Dornan D, Wertz I, Shimizu H, Arnott D, Frantz GD, Dowd P, et al. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 2004;429:86–92.CrossRefPubMed

26.

Corcoran CA, Huang Y, Sheikh MS. The p53 paddy wagon: COP1, PIRH2, and MDM2 are found resisting apoptosis and growth arrest. Cancer Biol Ther. 2004;3:721–5. https://doi.org/10.1038/nature02514.CrossRefPubMed

27.

Wertz IE, O’Rourke KM, Zhang Z, Dornan D, Arnott D, Deshaies RJ, et al. Human de-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science. 2004;303:1371–4. https://doi.org/10.1126/science.1093549.CrossRefPubMed

28.

Shao J, Teng Y, Padia R, Hong S, Noh H, Xie X, et al. COP1 and GSK3beta cooperate to promote c-Jun degradation and inhibit breast cancer cell tumorigenesis. Neoplasia. 2013;15:1075–85. https://doi.org/10.1593/neo.13966.CrossRefPubMedPubMedCentral

29.

Li DQ, Ohshiro K, Reddy SD, Pakala SB, Lee MH, Zhang Y, et al. E3 ubiquitin ligase COP1 regulates the stability and functions of MTA1. Proc Natl Acad Sci USA. 2009;106:17493–8. https://doi.org/10.1073/pnas.0908027106.CrossRefPubMed

30.

Ray D, Murphy KR, Gal S. The DNA binding and accumulation of p53 from breast cancer cell lines and the link with serine 15 phosphorylation. Cancer Biol Ther. 2012;13:848–57. https://doi.org/10.4161/cbt.20835.CrossRefPubMedPubMedCentral

31.

Graves B, Thompson T, Xia M, Janson C, Lukacs C, Deo D, et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA. 2012;109:11788–93. https://doi.org/10.1073/pnas.1203789109.CrossRefPubMed

Titel: The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines
Publikationsdatum: 07.03.2018
Erschienen in: Breast Cancer / Ausgabe 5/2018
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-018-0849-5

Springer Medizin

The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Comparison of sentinel lymph node biopsy between invasive lobular carcinoma and invasive ductal carcinoma

LncRNA PlncRNA-1 overexpression inhibits the growth of breast cancer by upregulating TGF-β1 and downregulating PHGDH

Applying new Magee equations for predicting the Oncotype Dx recurrence score

Improvement in diagnostic performance of breast cancer: comparison between conventional digital mammography alone and conventional mammography plus digital breast tomosynthesis

Life quality of patients who underwent breast reconstruction after prophylactic mastectomy: systematic review

Interleukin-6 receptor inhibitor suppresses bone metastases in a breast cancer cell line

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie